Amylyx's Avexitide Phase III Win Sets Up FDA Filing for PBH Treatment

Amylyx Pharmaceuticals said its Phase III avexitide trial in post-bariatric hypoglycemia met its primary endpoint and all secondary endpoints. The successful pivotal data positions Amylyx to submit a New Drug Application to the FDA before year-end, materially advancing the therapy toward potential commercialization.